These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6356466)

  • 1. The mechanisms of action of ticlopidine.
    Bruno JJ
    Thromb Res Suppl; 1983; 4():59-67. PubMed ID: 6356466
    [No Abstract]   [Full Text] [Related]  

  • 2. Ticlopidine - an antiplatelet drug: effects in human volunteers.
    O'Brien JR; Etherington MD; Shuttleworth RD
    Thromb Res; 1978 Aug; 13(2):245-54. PubMed ID: 694843
    [No Abstract]   [Full Text] [Related]  

  • 3. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.
    Picard-Fraire C
    Thromb Res Suppl; 1983; 4():119-28. PubMed ID: 6356462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production.
    Lagarde M; Ghazi I; Dechavanne M
    Prostaglandins Med; 1979 Jun; 2(6):433-9. PubMed ID: 399526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
    Tuong CC; Ferrand C; Aubert D; Loubrie JC; Tuong A
    Biochem Pharmacol; 1982 Mar; 31(6):1147-50. PubMed ID: 7200772
    [No Abstract]   [Full Text] [Related]  

  • 6. Ticlopidine and platelet function.
    Lecompte T; Lecrubier C; Potevin F; Samama M
    Thromb Haemost; 1986 Jun; 55(3):437-8. PubMed ID: 3529484
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison between the antiaggregating effect of ticlopidine in whole blood, platelet-rich plasma and washed platelets of the rat.
    Randon J; Lefort J; Vargaftig BB
    Thromb Res; 1982 Apr; 26(1):13-20. PubMed ID: 7048623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets.
    Dunn FW; Soria J; Soria C; Thomaidis A; Lee H; Caen JP
    Agents Actions Suppl; 1984; 15():97-104. PubMed ID: 6091425
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine.
    Chevolet C; Grosdent JC; Reiters GM; Dresse A
    Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):310-1. PubMed ID: 6817725
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
    de Gaetano G; Bertelé V
    Agents Actions; 1984 Jan; 14(1):109-12. PubMed ID: 6702507
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets.
    Lalau Keraly C; Delautier D; Delabassee D; Chignard M; Benveniste J
    Thromb Res; 1984 Jun; 34(6):463-71. PubMed ID: 6740569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticlopidine as an experimental antithrombotic agent.
    Vallée E; Maffrand JP; Bernat A; Delebassée D; Tissinier A
    Agents Actions Suppl; 1984; 15():50-9. PubMed ID: 6592945
    [No Abstract]   [Full Text] [Related]  

  • 13. Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study.
    Gensini GF; Favilla S; Breschi C; Abbate R; Costanzo G; Neri Serneri GG
    Haemostasis; 1983; 13(5):294-300. PubMed ID: 6228500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet aggregation by a new agent, Ticlopidine.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
    Lecrubier C; Girard P; Noire P; Samama M
    Agents Actions Suppl; 1984; 15():60-7. PubMed ID: 6592946
    [No Abstract]   [Full Text] [Related]  

  • 16. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ticlopidine, a new platelet aggregation inhibitor in man.
    Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
    Clin Pharmacol Ther; 1975 Oct; 18(4):485-90. PubMed ID: 1100310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic action of ticlopidine: possible mechanisms.
    Gryglewski RJ; Korbut R; Swies J; Kostka Trabka E; Bieroń K; Robak J
    Eur J Pharmacol; 1996 Jul; 308(1):61-7. PubMed ID: 8836633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.
    Maeda K; Usuda M; Kawaguchi S; Shinzato T; Saito A; Ohta K; Kobayashi K; Ohbayashi S; Narita M
    Artif Organs; 1980 Feb; 4(1):30-3. PubMed ID: 7369892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.